Glucocorticoid Antagonist Treatment for Tobacco Use Disorder
Status:
Terminated
Trial end date:
2019-05-20
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to examine whether mifepristone, a medication with
glucocorticoid receptor antagonist activity, may be a potential treatment for Tobacco Use
Disorder (TUD). Mifepristone has already shown promise as a potential treatment for PTSD (1)
and alcohol use disorder (AUD) (2), but no previous studies have examined the therapeutic
potential of mifepristone for TUD. This will be a double-blind, placebo-controlled study on
the effects of a 7-day treatment with 600 mg mifepristone, or placebo, on cognitive function,
tobacco withdrawal severity, and smoking behavior.